Unknown

Dataset Information

0

Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure-Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism.


ABSTRACT: Apixaban is approved for treatment of venous thromboembolism (VTE) and prevention of recurrence. Population pharmacokinetics, pharmacokinetics-pharmacodynamics (anti-FXa activity), and exposure-response (binary bleeding and thromboembolic endpoints) of apixaban in VTE treatment subjects were characterized using data from phase I-III studies. Apixaban pharmacokinetics were adequately characterized by a two-compartment model with first-order absorption and elimination. Age, sex, and Asian race had less than 25% impact on exposure, while subjects with severe renal impairment were predicted to have 56% higher exposure than the reference subject (60-year-old non-Asian male weighing 85 kg with creatinine clearance of 100 mL/min). The relationship between apixaban concentration and anti-FXa activity was described by a linear model with a slope estimate of 0.0159 IU/ng. The number of subjects with either a bleeding or thromboembolic event was small, and no statistically significant relationship between apixaban exposure and clinical endpoints could be discerned with a logistic regression analysis.

SUBMITTER: Byon W 

PROVIDER: S-EPMC5445237 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure-Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism.

Byon W W   Sweeney K K   Frost C C   Boyd R A RA  

CPT: pharmacometrics & systems pharmacology 20170501 5


Apixaban is approved for treatment of venous thromboembolism (VTE) and prevention of recurrence. Population pharmacokinetics, pharmacokinetics-pharmacodynamics (anti-FXa activity), and exposure-response (binary bleeding and thromboembolic endpoints) of apixaban in VTE treatment subjects were characterized using data from phase I-III studies. Apixaban pharmacokinetics were adequately characterized by a two-compartment model with first-order absorption and elimination. Age, sex, and Asian race had  ...[more]

Similar Datasets

| S-EPMC6263664 | biostudies-literature
| S-EPMC8189985 | biostudies-literature
| S-EPMC4235474 | biostudies-literature
| S-EPMC4834605 | biostudies-literature
| S-EPMC8096533 | biostudies-literature
| S-EPMC6401636 | biostudies-literature
| S-EPMC5466505 | biostudies-literature
| S-EPMC5591798 | biostudies-literature
| S-EPMC6524888 | biostudies-other
| S-EPMC6263663 | biostudies-literature